Agarwal V, Sitholey P, Kumar S, Prasad M
Department of Psychiatry, King George's Medical College, Lucknow (U.P.), India.
Ment Retard. 2001 Aug;39(4):259-67. doi: 10.1352/0047-6765(2001)039<0259:DBPCTO>2.0.CO;2.
A 12-week, double-blind, randomized, placebo-controlled trial of oral clonidine in three fixed doses (4, 6, and 8 mcg/kg/day) using a crossover design was conducted with 10 children who had hyperkinetic disorder (mean age 7.6 years +/-.54). All had comorbid mental retardation. Both parents' ratings on the Parent Symptom Questionnaire and clinicians' ratings on the Hillside Behaviour Rating Scale showed a marked dose-related response to clonidine in hyperactivity, impulsivity, and inattention. Drowsiness was a common side effect of clonidine. It wore off by the 2nd to 4th week in most cases. Thus, clonidine is a safe and effective medication in young hyperkinetic children with comorbid mental retardation.
采用交叉设计，对10名患有多动障碍（平均年龄7.6岁±0.54岁）且均伴有智力发育迟缓的儿童进行了一项为期12周的双盲、随机、安慰剂对照试验，口服可乐定，设置三个固定剂量（4、6和8微克/千克/天）。父母在《父母症状问卷》上的评分以及临床医生在《山坡行为评定量表》上的评分均显示，可乐定在治疗多动、冲动和注意力不集中方面有明显的剂量相关反应。嗜睡是可乐定常见的副作用。在大多数情况下，这种副作用在第2至4周会逐渐消失。因此，可乐定对患有智力发育迟缓的多动儿童来说是一种安全有效的药物。
